Aurora Cannabis

Canaccord Genuity Acts as Lead-Left Bookrunner to Aurora Cannabis on its US$172.5 Million Bought Deal Public Offering of Units

Canaccord Genuity is pleased to announce that on June 1, 2022, Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB) closed its previously announced bought deal of units (the “Units”) of the Company (the “Offering”). In aggregate, the Company issued 70.4 million Units, at a price of US$2.45 per Unit for gross proceeds of approximately US$172.5 million, each Unit being comprised of one common share of the Company (a “Common Share”) and one common share purchase warrant of the Company (a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$3.20 per Warrant Share, subject to adjustment in certain events.

Aurora is global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives, driven by science and innovation, and with a focus on high-quality cannabis products.

Canaccord Genuity acted as lead-left bookrunner to the Offering. The Canaccord Genuity team included Steve Winokur, Genevieve Eccleston, Matthew Wiebe, Chrissy Hui and Matthew Peck from Investment Banking, with support from our Equity Capital Markets team, led by Jennifer Pardi and Len Sauer.